What does this Instagram video claim?
Joey Udovich says combining GHK-Cu with BPC-157 and TB-500 regrew her hair after losing it following hysterectomy and mastectomy. She credits GHK-Cu specifically with boosting collagen, brightening skin, and waking up dormant hair follicles.
The video presents this as a personal success story rather than medical advice. But it makes specific mechanistic claims about how these peptides work for hair growth and skin improvement.
Udovich positions this as a solution for post-surgical hair loss and stress-related thinning. The combination approach suggests synergistic effects between the three peptides.
What does the research actually show?
The evidence for these peptides in humans is extremely thin. GHK-Cu has some promising data, but mostly from cell culture and animal studies.
A 2012 study by Pickart et al. found GHK-Cu increased hair follicle size in mice by 22%. But human trials are scarce. One small 2007 study showed modest improvement in hair density after 3 months, but it only included 20 people.
BPC-157 and TB-500 have even weaker human evidence for hair growth. Most research focuses on wound healing and tissue repair in animal models. The few human studies don't specifically examine hair regrowth outcomes.
The combination approach Udovich describes hasn't been studied in clinical trials. We're essentially looking at three experimental compounds with limited human data being used together.
What are the regulatory concerns?
None of these peptides are FDA-approved for hair loss or cosmetic use. The FDA has issued warning letters to companies selling BPC-157 and TB-500 as dietary supplements.
GHK-Cu exists in a regulatory gray area. While copper peptides appear in some cosmetic products, injectable forms fall into murky territory. Quality control and purity can vary significantly between suppliers.
TB-500 is particularly problematic. It's derived from thymosin beta-4 and has been banned by the World Anti-Doping Agency since 2010. This suggests potential for significant biological effects, but also unknown risks.
What should you know about post-surgical hair loss?
Hair loss after major surgery is real and well-documented. Telogen effluvium typically occurs 2-4 months post-surgery due to physical stress, anesthesia, and hormonal changes.
Most post-surgical hair loss resolves within 6-12 months without intervention. The timing Udovich describes would align with natural recovery patterns, making it difficult to attribute improvements to the peptides.
Proven treatments for hair loss include minoxidil (FDA-approved in 2% and 5% concentrations) and finasteride for androgenic alopecia. These have decades of safety data and established efficacy rates.
For post-menopausal women specifically, hormone replacement therapy may help with hair thinning, though it carries its own risk profile that requires medical supervision.
The bigger picture
Udovich's experience might be genuine, but individual results don't constitute evidence. The peptide combination she's using lacks proper human studies and regulatory oversight.
If you're dealing with post-surgical hair loss, proven treatments with known safety profiles make more sense as first-line options. The experimental nature of these peptides means you're essentially participating in an uncontrolled trial on yourself.